Chongqing Peg-bio Biopharm Co., Ltd.
Clinical trials sponsored by Chongqing Peg-bio Biopharm Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug PA5 targets arginine to starve advanced cancers Results expected Feb 2027 (estimated)
- Weekly shot could help people with short bowel syndrome absorb more fluids Results expected Apr 2027 (estimated)
- Experimental enzyme injection aims to tame PKU's toxic amino acid Results expected Jun 2027 (estimated)
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase 1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug FT1 tested for safety in healthy volunteers
Symptom relief CompletedThis early-stage study tested the safety of a new drug called FT1 in 60 healthy adults aged 18 to 45. Participants received either FT1 or a placebo injection. The goal was to see if FT1 is safe and how the body processes it.
Phase 1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC